Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : New drug entities : Amgen inc. save search
New Drug Delivery Systems Market 2022-2026 | Rising Prevalence Of Chronic Diseases to Boost Growth | Technavio
Published: 2022-03-02 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -6.92%
H: 1.86%
C: 1.86%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -5.26%
H: 0.0%
C: 0.0%
MDT | $79.445 0.32% 5.1M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: 0.28%
H: 0.54%
C: -0.33%
ABT | News | $107.4 2.02% 6.4M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
SNY | News | $46.385 2.19% 3M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.63%
H: 0.9%
C: -0.3%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 2.3%
H: 0.0%
C: 0.0%
new drug drug liver system disease growth drug delivery
New Drug Effective Against Lung Cancers Caused by Common Genetic Error
Published: 2021-06-04 (Crawled : 19:00) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
new drug genetic lung cancer cancer drug
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
Published: 2021-05-05 (Crawled : 14:15) - biospace.com/
BGNE | $129.42 -1.93% 180K
|
Health Technology
|
| O: -0.5%
H: 3.2%
C: -1.07%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: 1.24%
new drug fda drug psoriasis fda acceptance application plague
Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis
Published: 2021-02-22 (Crawled : 14:12) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.59%
H: 1.51%
C: 0.49%
drug new drug psoriasis application plague
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
Published: 2020-12-16 (Crawled : 21:11) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.3%
H: 0.99%
C: 0.93%
fda cancer drug lung cancer new drug application
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
ASNS | $0.828 21.75% 17.86% 18K
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
RWOD | $9.54 19.3% 16.18% 6.1M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.